News
Idarucizumab Effective for Dabigatran Reversal in Emergency Situations
Effective for dabigatran reversal among patients with uncontrolled bleeding, undergoing urgent surgery
Your search for dabigatran returned 116 results
News
Intraocular Hemorrhage Occurrence for Novel vs. Traditional Antithrombotic Agents
The researchers found that the risk of developing an intraocular hemorrhage was reduced with dabigatran or rivaroxaban at 365 days (hazard ratio, 0.75; 95% confidence interval, 0.58 to 0.97; P=0.03) but not at 90 days (hazard ratio, 0.73; 95% confidence interval, 0.22 to 2.63; P=0.13).
Uncategorized
Pradaxa Label Updated with New Contraindication
Boehringer Ingelheim announced that the prescribing information for Pradaxa (dabigatran etexilate mesylate) capsules was updated to include a contraindication related to use in patients with mechanical prosthetic heart valve replacement.
ACC.17
Anticoagulants Compared in A-fib Patients Undergoing Catheter Ablation
Study patients were randomized to Pradaxa 150mg twice daily or warfarin (target INR 2-3) and remained on this treatment for the trial duration.
News
Interim Data Reported on Pradaxa vs. Warfarin and Major Bleeding Events
Interim results of a retrospective analysis comparing major bleeding events in patients treated with Pradaxa (dabigatran etexilate mesylate; Boehringer Ingelheim) and warfarin were announced at the American Heart Association's Scientific Session 2014.
Drug News
Novel Oral Anticoagulant Use Increasing in A-Fib
For patients with atrial fibrillation hospitalized with stroke or transient ischemic attack, use of novel oral anticoagulants (NOACs) has increased over time.
News
Pradaxa 150mg available for stroke risk reduction
Pradaxa (dabigatran etexilate capsules) 150mg, an oral direct thrombin inhibitor, will be made available by Boehringer Ingelheim on November 3, 2010.
Drugs in the Pipeline
Priority Review Granted for Pradaxa Reversal Agent
The Food and Drug Administration (FDA) has granted Priority Review to the Biologics License Application (BLA) for idarucizumab (Boehringer Ingelheim) to reverse the anticoagulant effect of Pradaxa (dabigatran etexilate mesylate) in patients needing emergency intervention or experiencing an uncontrolled or life-threatening bleeding event.
Uncategorized
FDA Emphasizes Special Storage and Handling Requirements for Pradaxa
The FDA is alerting healthcare providers and patients of important storage and handling requirements for Pradaxa (dabigatran etexilate mesylate capsules; Boehringer Ingelheim).
News
Safety of Direct Oral Anticoagulants Versus Warfarin Investigated
Compared with warfarin, apixaban was correlated with reduced risk of major bleeding and intracranial bleeding (adjusted hazard ratios, 0.66 and 0.4, respectively) and dabigatran was correlated with reduced risk of intracranial bleeding (adjusted hazard ratio, 0.45) among patients with atrial fibrillation.
